Admedus pioneered the proprietary ADAPT® technology, invented by our Professor Leon Neethling, which is used to manufacture biomaterial scaffolds.
ADAPT® products – sold globally under the product names CardioCel, CardioCel Neo, CardioCel 3D and VascuCel – are currently used by surgeons around the world to treat patients with congenital heart defects and those in need of heart valve, vessel and cardiovascular repairs and peripheral vascular reconstruction.
Admedus’ ADAPT® tissue products are clinically superior – the best in their field – and the only product of their kind to have achieved nine years without calcification or degradation – a significant benefit to patients who would otherwise be forced to undergo recurrent operations.
Our flagship product, CardioCel®, an implantable bio-prosthetic patch, is currently delivering positive health outcomes for patients in more than 135 global centres in Europe, US, Canada, Singapore, Malaysia, Hong Kong, India and the Middle East.
We also have clearance to market VascuCel® and CardioCel® 3D, the world’s first curved biological tissue product, in the United States; a new distribution agreement in India; and the appointment of a distributor for the Middle East with the first sales of CardioCel® in Saudi Arabia.
Our manufacturing facility has substantial capacity to expand and includes an in-house research and development laboratory, so our company can achieve its goal of establishing a portfolio of regenerative products for significant world markets.
Pending regulatory approval, we’re also preparing to launch the ADAPT® portfolio into new markets such as Australia, Thailand, Vietnam, Philippines and Taiwan and have commenced the regulatory approval process in China.